Histone Deacetylase Inhibitors Market size is poised to reach USD 3 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of histone deacetylase inhibitors was USD 1.20 Billion. The reason behind the growth is impelled by the rising cases of cancer across the globe. HDAC inhibitors that allow acetylation equilibrium to be restored may be helpful in the treatment of cancer as they are similar to other anti-cancer medications, and are widely being used as a single agent or in combination with other chemotherapeutics in the treatment of tumors by promoting tumor cell death. By 2040, there will be more than 25 million new instances of cancer annually throughout the world.
The growing research & development activities for the development of advanced drugs are believed to fuel the growth of histone deacetylase inhibitors market. The creation of HDAC inhibitors has become a key tactic in the design of novel therapies that are being developed as a new, focused class of anticancer medications and several HDAC inhibitors (HDAC) have already been approved by the Food and Drug Administration (FDA) and are now being tested in clinical settings for a variety of cancers.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~8% |
|
Base Year Market Size (2023) |
~ USD 1.20 Billion |
|
Forecast Year Market Size (2036) |
~ USD 3 Billion |
|
Regional Scope |
|
Route of Administration (Oral HDAC Inhibitors, Parenteral HDAC Inhibitors)
The oral histone deacetylase inhibitors market is estimated to hold 55% of the revenue share during the forecast period owing to the huge availability of orally HDAC inhibitors. The epigenetic agents known as histone deacetylase inhibitors (HDAC inhibitors, HDACi, HDIs) are pharmacological substances that induce the cell cycle gene p21 to be upregulated and are in recent development in the field of drug research.
Oral HDAC (Histone Deacetylase) inhibitors are a type of medication that can have several potential benefits, including the ability to regulate gene expression and offer a broad spectrum of anticancer action.
The oral HDAC inhibitor valproic acid (VPA) inhibits HDAC which suppresses the cell growth of small-cell lung cancer. Additionally, TYA-018 is a very effective and specific HDAC6 inhibitor that can be used orally that improve energetics in mice by boosting the expression of genes. Furthermore, The HDAC inhibitor panobinostat is a powerful and non-selective oral agent that increases HIV-1 expression in cells that are latently infected and may be employed for the investigation of refractory or relapsed multiple myeloma. Besides this, the parenteral HDAC inhibitors segment is anticipated to gain significant share during the forecast timeframe.
Application (Oncology, Neurology)
Histone deacetylase inhibitors market from the oncology electronics segment is set to garner a notable share shortly. HDAC inhibitors hold a promising avenue in the field of oncology as ongoing research and clinical trials are continually exploring their effectiveness in treating different types of cancers, contributing to the rise in demand. Moreover, HDAC, a novel class of anticancer therapeutic targets, has received extensive research since it causes tumor cell death with all of the morphological and cellular hallmarks of apoptosis and can also reverse the aberrant acetylation state of proteins present in cancer cells.
End-User (Hospitals, Homecare, Specialty Clinics)
The hospitals segment in the histone deacetylase inhibitors market is poised to gain a robust revenue share by the year 2036. Hospitals are increasingly requesting HDAC (Histone Deacetylase) inhibitors as a result of their ability to treat a variety of malignancies since some cancer treatments still include care as a crucial component, and cancer surgery outcomes are better in hospitals with greater infrastructure and resources.
Our in-depth analysis of the global histone deacetylase inhibitors market includes the following segments:
|
Classification |
|
|
Application |
|
|
Drugs |
|
|
End-User |
|
|
Distribution Channel |
|
|
Route of Administration |
|
North American Market Forecast
Histone deacetylase inhibitors market in North America is predicted to account for the largest share of 35% by 2036 impelled by rising investment in healthcare. This has led to a rise in research & development capacities for the development of advanced drugs including HDAC inhibitors in the region. According to estimates, spending on healthcare in the United States in 2021 was more than USD 4 trillion, or around USD 12,800 per person.
APAC Market Statistics
The APAC histone deacetylase inhibitors market is estimated to be the second largest, during the forecast timeframe led by rising governmental initiatives to create cancer awareness. For instance, The National Cancer Grid (NCG) was established to unite cancer treatment facilities across India to establish uniform patient care standards for cancer prevention, diagnosis, and treatment, and offer specialized oncology training and education to ensure that patients from all regions of the nation receive the same high-quality care without having to travel far or worry about their ability to pay for treatment.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?